GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Neuraxis Inc (AMEX:NRXS) » Definitions » Debt-to-Equity

Neuraxis (Neuraxis) Debt-to-Equity : -0.55 (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Neuraxis Debt-to-Equity?

Neuraxis's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $1.43 Mil. Neuraxis's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.31 Mil. Neuraxis's Total Stockholders Equity for the quarter that ended in Mar. 2024 was $-3.18 Mil. Neuraxis's debt to equity for the quarter that ended in Mar. 2024 was -0.55.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Neuraxis's Debt-to-Equity or its related term are showing as below:

NRXS' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.55   Med: -0.16   Max: 0.19
Current: -0.55

During the past 4 years, the highest Debt-to-Equity Ratio of Neuraxis was 0.19. The lowest was -0.55. And the median was -0.16.

NRXS's Debt-to-Equity is not ranked
in the Biotechnology industry.
Industry Median: 0.14 vs NRXS: -0.55

Neuraxis Debt-to-Equity Historical Data

The historical data trend for Neuraxis's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neuraxis Debt-to-Equity Chart

Neuraxis Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Debt-to-Equity
0.19 -0.53 -0.11 -0.16

Neuraxis Quarterly Data
Dec20 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.09 -0.17 -0.26 -0.16 -0.55

Competitive Comparison of Neuraxis's Debt-to-Equity

For the Biotechnology subindustry, Neuraxis's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Neuraxis's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Neuraxis's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Neuraxis's Debt-to-Equity falls into.


Neuraxis Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Neuraxis's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0.197 + 0.027) / -1.403
=-0.16

Neuraxis's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(1.432 + 0.314) / -3.184
=-0.55

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Neuraxis  (AMEX:NRXS) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Neuraxis Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Neuraxis's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Neuraxis (Neuraxis) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Neuraxis Inc (AMEX:NRXS) » Definitions » Debt-to-Equity
Comparable Companies
GTBP ALZN VIRI EDSA VYNE ARAV OGEN DOMH TNXP NHWK OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
N/A
Address
11550 N. Meridian Street, Suite 325, Carmel, IN, USA
Website
http://www.neuraxis.com
Neuraxis Inc is a growth stage company focused on developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology.
Executives
Masimo Corp 10 percent owner 52 DISCOVERY, IRVINE CA 92618
John G Seale officer: CHIEF FINANCIAL OFFICER 10038 OXFORD PIKE, BROOKVILLE IN 47012
Brian Allen Carrico director, officer: CEO, DIRECTOR 11550 NORTH MERIDIAN STREET, SUITE 325, CARMEL IN 46032
Christopher Robin Brown director, officer: DIRECTOR OF INNOVATION 829 S. ADAMS ST, VERSAILLES IN 47042
Daniel Jerome Clarence officer: CHIEF OPERATING OFFICER 10461 W GRANDVIEW DRIVE, COLUMBUS IN 47201
Thomas Joeseph Carrico officer: CHIEF REGULATORY OFFICER 829 S. ADAMS ST., VERSAILLES IN 47042
Gary Merril Peterson officer: DIR.OF DESIGN & ENGINEERING 829 S. ADAMS ST., VERSAILLES IN 47042
Bradley Mitchell Watkins director 10322 MEDICIS PLACE, WELLINGTON FL 33449
Jane Elizabeth Keyser director 220 VIRGINIA AVENUE, INDIANAPOLIS IN 46204
Timothy Robert Henrichs director 324 LEITCH AVENUE, LA GRANGE IL 60525
Adrian Miranda officer: Chief Medical Officer, SVP 829 S. ADAMS STREET, VERSAILLES IN 47042